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Abstract:
Purpose The purpose of this study is to analyze the US FDA Adverse 
Event Reporting System (FAERS) to identify adverse cardiac events of 
hydroxychloroquine in older adults. 
Method A case/non-case method was used to determine adverse events 
associated with hydroxychloroquine as the primary suspect drug 
between January 1, 2004, and December 31, 2019, for older adults (≥ 
65 years). Adverse events are preferred terms (PTs) defined in MedDRA. 
We used frequentist approaches, including the reporting odds ratio 
(ROR) and the proportional reporting ratio (PRR) to measure 
disproportionality. We used Bayesian approaches to derive information 
component (IC) value and Empirical Bayesian Geometric Mean (EBGM) 
score. Signals were defined as the number of reports>3 and the lower 
limit of 95% confidence intervals (CI) of ROR ≥2, PRR ≥2, IC >0, 
EBGM>1 
Results We identified 334 adverse cardiac events comprising 71 different 
MedDRA PTs from 2004 to 2019 for hydroxychloroquine in older adults. 
Strong disproportionality signals were noted for ‘Restrictive 
cardiomyopathy’ (ROR= 272.43 (138.09-537.47); EBGM= 149.78 
(77.34-264.67), ‘Right ventricular hypertrophy’ (219.49 (85.32-564.70); 
102.74 (39.67-222.81), ‘Cardiac septal hypertrophy’ (226.77 (78.65-
653.80); 93.82 (32.19-219.81), ‘Myocardial fibrosis’ (57.29 (21.06-
155.85); 42.99 (14.74-100.75), and ‘Cardiotoxicity’ (43.90 (26.66-
72.27); 40.28 (24.02-63.72). 
Conclusions The risk of cardiomyopathy and myocardial disorders is high 
following exposure to hydroxychloroquine in older adults. Due to the 
current lack of safety data from randomized controlled trials as well as 
large observational studies to confirm the risk of adverse cardiac events 
associated with hydroxychloroquine, findings from analyses of post-
marketing data may serve as interim guidance. 
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Thank you for the opportunity to revise our paper and clarify the comments raised by the 
reviewers. We are grateful for the useful comments provided by the reviewers to improve the 
manuscript, and the reviewers share our judgement that the findings of this study are 
interesting and important. Please see below, in blue, our detailed response to comments. All 
page numbers refer to the manuscript file with tracked changes
Reviewer 1:
Comments to the Author
Abstract
- RORs that high with a wide confidence interval represents a lack of sample size and 
very hard to interpret.
Response 1
We acknowledge this is a limitation of the study. However, the signals meet the criteria for a 
disproportionality signal- defined as the number of reports >3 and the lower limit of 95% 
confidence intervals (CI) of ROR ≥2, PRR value ≥2, IC value >0 and EBGM score >1. 
We have also added the following sentence to the limitations paragraph of the Discussion on 
page
Page 7, Line 32-35: ‘The ROR’s for ADE’s associated with hydroxychloroquine with a wide 
confidence interval represents a lack of sample size, and the safety signals must be 
interpreted with this limitation. The safety signals reported in this study with 
hydroxychloroquine do not impart causality.”
- Please rewrite the timeframe of the study such as January 1, 2004, etc. rather than 
the current format given the variability of dating convention worldwide.
Response 2
Page 4, Line 22-23: We agree with the reviewer and accordingly have changed the date 
format.
Introduction
Please reframe the message to NOT-TO-IMPART causality. FAERS database is meant 
for exploratory analyses – that is – to generate hypotheses rather than testing 
hypotheses.
Response 3.
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We agree with the reviewer and appended the following sentence to the introduction:
Page 3, Line 32-33: “The FAERS data is widely used in drug safety research for exploratory 
analyses to generate hypotheses and safety signals reported do not impart causality.”
Page 7, Line 32-35: “The safety signals reported in this study with hydroxychloroquine do not 
impart causality.”
Methods
- Was the primary suspect outcomes were reported or primary OR secondary suspect 
outcomes were considered?
Response 4
Outcomes such as disability or hospitalisations were not analysed in the study. 
We analysed all reported adverse events in older adults with hydroxychloroquine as the 
primary suspect drug.  Concomitant drugs ( secondary suspect drugs) were not included in 
the analyses.
- Were the authors able to identify for which indication hydroxychloroquine (HCQ) 
was prescribed? The method section mentions that. How many missing values were 
there? How it was relevant to the study?
Response 5
Indications were missing for 97 out of 1090 (8.9%) reports. The majority of the reports 
430/1090 (39.4%) indicated hydroxychloroquine was used for rheumatic disorders (mainly 
rheumatoid arthritis) followed by 124/1090 (11.3%) reports for systemic lupus erythematosus. 
We analysed all reported adverse events with hydroxychloroquine as the primary suspect drug 
in older adults regardless of the indication of its use during the study period. The missing 
indications for hydroxychloroquine did not have any impact on safety signals generated for 
hydroxychloroquine.
We appended the following sentence to the results:
Page 5, Line 9-13: “Indications were missing for 97 out of 1090 (8.9%) reports. The majority 
of the reports 496/1090 (45.5%) indicated hydroxychloroquine was used for rheumatic 
disorders (mainly rheumatoid arthritis) followed by 124/1090 (11.3%) reports for systemic 
lupus erythematosus, and 199/1090 (18.3%) reports recorded hydroxychloroquine was used 
for an unknown indication.”
- How HCQ was identified? What string searches were used and/or how? How the 
misspellings (if any) were corrected?
Response 6
Data were retrieved from the Elsevier PharmaPendium database. The use of PharmaPendium 
for drug safety research is described elsewhere. The data is curated by an experienced team 
of data analysts at Elsevier and is made ready for analyses.
- How the duplicate reports were handled? Are these worldwide reports or just US 
reports?
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We identified duplicate reports based on CaseID, Primary Suspect Drugs, Gender, Age and 
Location. The analyses included reports from the USA and worldwide.
Results & Discussion
- Please describe why only older adults were chosen for the study. COVID-19 is 
causing major cardiac events in younger adults as well. This would be a very 
important clinical implication of this study.
Response 8
We have appended the following paragraph to the discussion to highlight the importance of 
COVID-19 related risks in older adults.
Page 5, Line 31-34 & Page 6, Line 1: “The risk for severe illnesses from COVID-19 infection 
is age-related, with older adults aged 85 or older at highest risk. Underlying medical 
comorbidities, specifically underlying cerebrovascular and cardiovascular disease, including 
heart failure, coronary heart disease and cardiomyopathies, increases the risk of 
hospitalisations and intensive care unit admissions in older adults with COVID-19 infection.”
- The authors should comment on the extremely high RORs and a wide confidence 
interval in terms of statistical consideration as well as clinical considerations. These 
are almost uninterpretable.
Response 9
Please note Response 1. We have discussed this as a study limitation.
- The authors should write the limitation of this study more precisely. There are many 
studies that provided a big description of the limitations of the FAERS database, and 
this current study should interpret and discuss the results based on the limitations. I 
would recommend depicting the limitation of this study and format the discussion. I 
am providing a citation for the authors’ convenience –
Clin Drug Investig. 2017 Dec; 37(12): 1143–1152.
Response 10
We thank the reviewer for pointing us to this relevant citation. The study limitations outlined in 
the study conducted by Rahman et al. on the FAERS database are pertinent to our 
investigation. We have formatted our discussion based on the limitations discussed by 
Rahman et al. 
We have revised the limitations section as follows.
Page 7, Line 17-35: “There are database and several methodological limitations associated 
with this study. Adverse event reports are submitted voluntarily to FAERS, and this may 
potentially lead to underreporting. Although careful consideration was given to the removal of 
duplicated reports, there is a possibility that the AEs may be reported multiple times by various 
stakeholders including patients, manufacturers and physicians.   Given the spontaneous 
nature of reporting, the drug exposure at a population level is unknown, hence the actual 
incidence rate for the AE cannot be established. Lack of information on comorbidities, family 
history, and incomplete dosage information is likely to bias the study findings. Characteristic 
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of SRS is the potential for selective reporting of only serious adverse events. Specific 
methodological limitations include examining hydroxychloroquine as the primary drug of 
interest without ascertaining the impact of concomitant medications on the AE. Several of the 
AEs identified with hydroxychloroquine may be confounded by the severity of the underlying 
medical condition. For example, several autoimmune disorders treated with 
hydroxychloroquine are independently associated with adverse cardiac outcomes. It is 
important to note that we did not investigate a dose-dependent or a temporal relationship with 
AEs, as these are significant risk factors for cardiac AEs with hydroxychloroquine. Hence the 
safety signals reported with hydroxychloroquine do not impart causality.”
Reviewer 2
This is an interesting paper and I have some comments for the authors consideration:
We appreciate the encouraging comment.
Abstract: Why are you examining cardiac events in hydroxychloroquine in older 
adults? Have clinical trials not examined this population? You need to be specific in 
the purpose of the study.
Response 11
We thank the reviewer for their suggestion. Given the word count limit in the abstract 
section, we have clarified the purpose of the study in the introduction. 
Page 3, Line 15-29: “COVID-19 disproportionately affects older adults. Given the repurposing 
of hydroxychloroquine has gained rapid interest for the treatment of COVID-19, understanding 
safety profile of hydroxychloroquine from post-marketing data is of paramount importance. 
This is particularly important as there is a lack of safety data for hydroxychloroquine from 
randomized controlled trials (RCTs) or observational studies (7). Specifically, there is a lack 
of safety data from RCTs for older adults using hydroxychloroquine for the treatment of 
COVID-19 infection caused by SARS-CoV-2 (8, 9). A recent RCT conducted in USA and 
Canada showed that hydroxychloroquine was not effective when offered as prophylaxis after 
COVID-19 exposure. In this RCT (N=821), the median age of the study population was 41 
(IQR=33 to 51) years with no safety data reported for hydroxychloroquine use in older adults 
(9).  A more recent RCT conducted over eight weeks that evaluated the efficacy and safety of 
hydroxychloroquine versus placebo for pre-exposure SARS-CoV-2 prophylaxis among health 
care workers showed no clinical benefit of hydroxychloroquine (10). The median age of the 
study population in this RCT was 33 (20-66), and there was no safety data for 
hydroxychloroquine reported in older adults.”
Introduction, page 4, line 10: This drug candidate list seems slightly out of date now- 
lopinavir/ritonavir and ivermectin are not really leading candidates anymore. Perhaps 
use a more up to date reference. Remdesivir is also spelt incorrectly.
Response 12
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We thank the reviewer for this suggestion and accordingly revised the sentence and updated 
the reference. We regret that we had misspelt Remdesivir. It is now amended in the revised 
manuscript.
Introduction: It may be worth mentioning that the FDA has subsequently withdrawn 
the emergency use authorisation. Also, be more specific about what data is lacking 
for hydroxychloroquine- data does exist for other indications aside from COVID. Is it 
that there is not RCT data for older adults using hydroxychloroquine at all (regardless 
of indication)? It is a generalisation to say they are usually excluded.
Response 13
We have updated the introduction to clarify that the FDA has withdrawn the emergency use 
authorisation of hydroxychloroquine. 
There is limited RCT data f r older adults using hydroxychloroquine, regardless of indication. 
We have appended the following paragraph in the introduction.
Page 3, Line 21-24: “A recent RCT conducted in USA and Canada showed that 
hydroxychloroquine was not effective as postexposure prophylaxis after COVID-19 exposure. 
In this RCT, the median age of the study population (N=821) was 41(IQR=33 to 51) years with 
no safety data reported for hydroxychloroquine use in older adults [7]. ”
Discussion: The authors comment on the known cardiac effects of 
hydroxychloroquine. I think this could be expanded to explicitly state why older 
adults may be at greater risk, referring to prevalence of cardiac disease in this age 
group. Also, are they likely to experience more serious outcomes from these types of 
events e.g. death? The authors need to be clear why these events are of greater 
concern in older adults, as many of these events would be of concern among any age 
group.
Response 14
The risk for severe illness from COVID-19 increases with age, with older adults aged 85 or 
older at highest risk. Underlying medical comorbidities, specifically underlying cerebrovascular 
and cardiovascular disease including heart failure, coronary heart disease and 
cardiomyopathies means that an older adult with COVID-19 may require hospitalisation and 
subsequent admission to the intensive care unit. 
We appended the following paragraph into the discussion.
Page 6, Line 15-23: “Also, two recent studies have lighted the risk of QT interval prolongation 
in patients with COVID-19 infection treated with hydroxychloroquine. In a case series of 
intensive care unit patients (median age= 68 years (IQR, 58-74 years)) admitted for COVID-
19 infection, those treated with hydroxychloroquine had an increased risk of QT prolongation. 
Similar findings were echoed in a cohort study conducted at a tertiary care hospital in Boston, 
Massachusetts, involving 90 patients with mean age 60 years (SD=16). In this cohort study, 
patients who received hydroxychloroquine for the treatment of pneumonia associated with 
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COVID-19 were at high risk of QTc prolongation.  The most common underlying comorbidities 
in this cohort included hypertension and diabetes.”
Discussion: Regarding the novel findings, why are these events of concern? Are they 
more likely to result in death than the known events? Safety signals need to be 
discussed in terms of their importance, not just their presence
Response 15
We appreciate the importance of communicating the impact of safety signals on clinical 
outcomes. Accordingly, we have appended the following information to the discussion.
Page 6, Line 34-35 & Page 7 Line 1-4: “Cardiac septal hypertrophy in older adults is associated 
with disturbance in intraventricular conduction and is an independent predictor of progression 
to atrial fibrillation in patients with hypertrophic cardiomyopathy. [23, 24]. Myocardial fibrosis 
is a significant risk factor for hypertrophic cardiomyopathy, and is associated with a myriad of 
severe adverse cardiovascular outcomes including sudden cardiac death, ventricular 
tachyarrhythmias, left ventricular dysfunction, and heart failure [25].”
Discussion, limitations: Can the authors comment on whether masking of signals may 
be present and could have any influence on study results? The limitations should 
also explicitly state why causality cannot be inferred from these results.
Response 16
We did not explore whether the masking influenced the safety signals for hydroxychloroquine. 
One study (Wang HW, Hochberg AM, Pearson RK, Hauben M. An experimental investigation 
of masking in the US FDA adverse event reporting system database. Drug Saf. 2010 Dec 
1;33(12):1117-33) has reported that the prevalence of masking might be low in the Adverse 
Event Reporting System and is more likely to occur in pharmaceutical company databases. 
Another challenge is accurately identifying drug candidates in the FAERS that are likely to 
mask signals. We do not feel that this limitation is expected to be significant for the reasons 
outlined above. On balance, we cannot make a definitive comment if masking of signals 
influenced the study findings. 
Please note our response 10 to reviewer 1 in which we have discussed the limitations of the 
study and the reasons causality cannot be inferred. 
Conclusions: I agree that monitoring signals is important but they should also be 
investigated further where there is a concern, using other study methods where 
required. You mention screening in the conclusion but have not discussed this 
elsewhere- you should include a paragraph in the discussion outlining this 
recommendation in more detail. What screening is needed? Who will this help? How 
will this mitigate complications?
Response 17
We thank the reviewer for their valuable suggestion. We have appended the following 
paragraph in conclusion. 
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Page 8, Line 5-10: “The American College of Cardiology's as well as the Canadian heart 
rhythm society recommendation is that patients with COVID-19 infection treated with 
hydroxychloroquine should undergo a careful assessment of baseline risk of QT prolongation, 
including baseline ECG, biochemical tests, and exclusion of concomitant drugs that have a 
potential to prolong QTc interval to mitigate further complications such as torsades de pointes 
[8].”
Conclusions: You need to be clear that any lack of safety data is specifically for the 
age group (older adults) and the COVID indication. Hydroxychloroquine would not be 
authorised for other indications without sufficient safety data in these other 
populations. Please be clear on this throughout the manuscript.
Response 18
We thank the reviewer for pointing this out and have attempted to clarify this message 
throughout the manuscript.
We have appended the following sentence in the introduction
Page 3, Line 19-21: “Specifically, there is a lack of safety data for older adults using 
hydroxychloroquine for the treatment of COVID-19 infection caused by SARS-CoV-2.”
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19 Key points
20 1. The study found that the risk of cardiac cardiomyopathy and myocardial disorders is high 
21 following exposure to hydroxychloroquine in older adults.
22 2. Novel findings include the identification of a signal for cardiac septal hypertrophy.
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2 Purpose The purpose of this study is to analyze the US FDA Adverse Event Reporting System 
3 (FAERS) to identify adverse cardiac events of hydroxychloroquine in older adults.
4 Method A case/non-case method was used to determine adverse events associated with 
5 hydroxychloroquine as the primary suspect drug between January 1, 2004, and December 31, 
6 2019, for older adults (≥ 65 years). Adverse events are preferred terms (PTs) defined in 
7 MedDRA. We used frequentist approaches, including the reporting odds ratio (ROR) and the 
8 proportional reporting ratio (PRR) to measure disproportionality. We used Bayesian 
9 approaches to derive information component (IC) value and Empirical Bayesian Geometric 
10 Mean (EBGM) score. Signals were defined as the number of reports>3 and the lower limit of 
11 95% confidence intervals (CI) of ROR ≥2, PRR ≥2, IC >0, EBGM>1 
12 Results We identified 334 adverse cardiac events comprising 71 different MedDRA PTs from 
13 2004 to 2019 for hydroxychloroquine in older adults. Strong disproportionality signals were 
14 noted for ‘Restrictive cardiomyopathy’ (ROR= 272.43 (138.09-537.47); EBGM= 149.78 
15 (77.34-264.67), ‘Right ventricular hypertrophy’ (219.49 (85.32-564.70); 102.74 (39.67-
16 222.81), ‘Cardiac septal hypertrophy’ (226.77 (78.65-653.80); 93.82 (32.19-219.81), 
17 ‘Myocardial fibrosis’ (57.29 (21.06-155.85); 42.99 (14.74-100.75), and ‘Cardiotoxicity’ (43.90 
18 (26.66-72.27); 40.28 (24.02-63.72).
19 Conclusions The risk of cardiomyopathy and myocardial disorders is high following exposure 
20 to hydroxychloroquine in older adults. Due to the current lack of safety data from randomized 
21 controlled trials as well as large observational studies to confirm the risk of adverse cardiac 
22 events associated with hydroxychloroquine, findings from analyses of post-marketing data 
23 may serve as interim guidance.
24
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2 The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 
3 (SARS-CoV-2) has positioned drug repurposing research on the spotlight (1, 2). Drug 
4 repurposing is investigating existing drugs for new indications, and several drugs have 
5 emerged as candidates for repurposing to treat COVID-19. Among the several leading 
6 candidates chloroquine, hydroxychloroquine and remdesivir have generated massive interest 
7 in the USA as a potential 'game-changer' in the treatment of COVID-19 (3, 4). Several clinical 
8 trials are being undertaken to generate evidence on the efficacy of hydroxychloroquine to treat 
9 COVID-19 patients (5).  Based on the research evidence from ongoing clinical trials, the US 
10 FDA  has removed the emergency use authorization for hydroxychloroquine and chloroquine 
11 for the treatment of COVID-19 given that the risks of using hydroxychloroquine for the 
12 treatment of COVID-19 infection outweigh any benefits (6). However, the uncertainty of the 
13 safety of hydroxychloroquine in older adults will endure given the historical evidence for the 
14 exclusion of older adults with comorbidities in clinical trials. 
15 COVID-19 disproportionately affects older adults. Given the repurposing of 
16 hydroxychloroquine has gained rapid interest for the treatment of COVID-19, understanding 
17 safety profile of hydroxychloroquine from post-marketing data is of paramount importance. 
18 This is particularly important as there is a lack of safety data for hydroxychloroquine from 
19 randomized controlled trials (RCTs) or observational studies (7). Specifically, there is a lack 
20 of safety data from RCTs for older adults using hydroxychloroquine for the treatment of 
21 COVID-19 infection caused by SARS-CoV-2 (8, 9). A recent RCT conducted in USA and 
22 Canada showed that hydroxychloroquine was not effective when offered as prophylaxis after 
23 COVID-19 exposure. In this RCT (N=821), the median age of the study population was 41 
24 (IQR=33 to 51) years with no safety data reported for hydrox chloroquine use in older adults 
25 (9).  A more recent RCT conducted over eight weeks that evaluated the efficacy and safety of 
26 hydroxychloroquine versus placebo for pre-exposure SARS-CoV-2 prophylaxis among health 
27 care workers showed no clinical benefit of hydroxychloroquine (10). The median age of the 
28 study population in this RCT was 33 (20-66), and there was no safety data for 
29 hydroxychloroquine reported in older adults.  The objective of this study is to analyze the US 
30 FDA Adverse Event Reporting System (FAERS), a publicly available database, to identify 
31 adverse cardiovascular events of hydroxychloroquine in older adults using analysis of 
32 disproportionality. The FAERS data is widely used in drug safety research for exploratory 
33 analyses to generate hypotheses and safety signals reported do not impart causality. 
34 Method:
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1 Ethics approval: The Departmental Research Ethical Officer at the University of Bath 
2 approved this study. 
3 Data source: Data was retrieved from the Elsevier PharmaPendium database (11). Data for 
4 4667+ United States FDA and European Medicines Agency approved drugs, and 14+ million 
5 FAERS reports have been collected and stored in the PharmaPendium in the latest 2020.07 
6 release. The use of PharmaPendium for drug safety research is described elsewhere (12, 13). 
7 Each FAERS report contains information on the drug and its role in the event, dose, frequency 
8 and route. The primary, secondary, concomitant and interacting drugs are reported.
9 Along with the adverse event experienced, the outcome, drug indication, reporter occupation, 
10 location of the event, manufacturer, patient gender and age are documented.  Each report has 
11 an AERS report number and Case ID aiding with easy identification. The Medical Dictionary 
12 for Regulatory Activities (MedDRA) was used to identify frequently implicated adverse drug 
13 events. 
14 Adverse drug reaction definition
15 We used the preferred terms (PTs) recommended in the Medical Dictionary of Regulatory 
16 Activities (MedDRA v2.0) to define adverse events associated with hydroxychloroquine. Each 
17 PT is part of the hierarchal system, linking to a higher-level term (HLT), higher-level group 
18 term (HLGT) and system organ class (SOC). 
19
20 Statistical Analyses
21 We selected hydroxychloroquine as the primary suspect drug and analyzed all reported 
22 adverse events in older adults from the start of January 1, 2004, to the end of December 31, 
23 2019. The ratio of cases/non-cases for hydroxychloroquine was compared with the ratio of 
24 cases/non-cases for all other drugs for the same study period. We used the disproportionality 
25 analyses to calculate the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) 
26 (14). We used the Bayesian approach to calculate information component (IC) values and 
27 Empirical Bayesian Geometric Mean (EBGM) scores. The criteria for a disproportionality 
28 signal was defined as the number of reports >3 and the lower limit of 95% confidence intervals 
29 (CI) of ROR ≥2, PRR value ≥2, IC value >0 and EBGM score >1. For secondary analyses, we 
30 mapped the PTs of adverse cardiovascular events to system organ class (SOC), high-level 
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1 We retrieved a total of 7,247,902 drug-event pairs between January 1, 2004, and December 
2 31, 2019, recorded in FAERS for adults aged ≥ 65 years by splitting multiple AEs reported for 
3 each case. Of which, 5327 adverse events (AEs) belonged to hydroxychloroquine. Amongst 
4 the 5327 AEs, we identified 334 adverse cardiac events comprising 71 different MedDRA PTs. 
5 The mean age of the patients within the reports (n=1090) for hydroxychloroquine is 71.77 
6 (7.27) years, and 85.4 % were females. 56.1% of the reports were submitted by 'other 
7 healthcare professionals' followed by 20.3% from physicians and 20.5% from consumers. 
8 90.4% of the reports were expedited. The country of origin of the reports was mostly from the 
9 USA.  Indications were missing for 97 out of 1090 (8.9%) reports. The majority of the reports 
10 430/1090 (39.4%) indicated hydroxychloroquine was used for rheumatic disorders (mainly 
11 rheumatoid arthritis) followed by 124/1090 (11.3%) reports for systemic lupus erythematosus, 
12 and 199/1090 (18.3%) reports recorded hydroxychloroquine was used for an unknown 
13 indication.
14 Figure 1. Mapping of hydroxychloroquine-associated all adverse drug events at different 
15 MedDRA levels: SOC: system organ class; HLGT: high-level group term; HLT: high-level term
16 Figure 2. Mapping of hydroxychloroquine-associated cardiovascular events at different 
17 MedDRA levels: SOC: system organ class; HLGT: high-level group term; HLT: high-level term. 
18 Yellow boxes include terms resulting in disproportionality signals; Grey boxes include terms 
19 without disproportionality; NEC: not elsewhere classified; MedDRA: Medical Dictionary for 
20 Regulatory Activities
21 Figure 3: RORs and EBGM scores with 95% CIs for PTs with hydroxychloroquine-
22 associated cardiovascular events. ADR-adverse drug reaction; HCQ-hydroxychloroquine 
23 ROR- reporting odds ratio; EBGM-Empirical Bayesian geometric mean; CI confidence 
24 interval.
25 Strong disproportionality signals were noted for ‘Restrictive cardiomyopathy’ (ROR= 272.43 
26 (138.09-537.47); EBGM= 149.78 (77.34-264.67), ‘Right ventricular hypertrophy’ (219.49 
27 (85.32-564.70); 102.74 (39.67-222.81), ‘Cardiac septal hypertrophy’ (226.77 (78.65-653.80); 
28 93.82 (32.19-219.81), ‘Myocardial fibrosis’ (57.29 (21.06-155.85); 42.99 (14.74-100.75), and 
29 ‘Cardiotoxicity’ (43.90 (26.66-72.27); 40.28 (24.02-63.72).
30 Discussion
31 The risk for severe illnesses from COVID-19 infection is age-related, with older adults aged 
32 85 or older at highest risk. Underlying medical comorbidities, specifically underlying 
33 cerebrovascular and cardiovascular disease, including heart failure, coronary heart disease 
34 and cardiomyopathies, increases the risk of hospitalizations and intensive care unit 
Page 14 of 37
http://mc.manuscriptcentral.com/pds































































1 admissions in older adults with COVID-19 infection (16). In this context, this study addressed 
2 the impending necessity emerging from the COVID-19 pandemic for understanding the safety 
3 of hydroxychloroquine in older adults. 
4 Majority of the cardiovascular AEs reported in this study are related to cardiac conduction and 
5 myocardial disorders. These findings are consistent with a recent systematic review that 
6 concluded conduction disorders and myocardial hypertrophy as two major cardiac 
7 complications associated with hydroxychloroquine therapy (17). 
8 Analyses of high-level MedDRA terms suggest that hydroxychloroquine therapy is associated 
9 with abnormal cardiac conduction, cardiac arrhythmias, and cardiomyopathy.  Several case 
10 reports have described proarrhythmic effects and signs of long QT syndrome following 
11 hydroxychloroquine exposure in patients with systemic lupus erythematosus (18, 19). The 
12 interim guidance from the Canadian heart rhythm society to mitigate drug-induced arrhythmias 
13 is for performing baseline ECG testing in high-risk patients. The recommendation is to optimize 
14 drug treatments, and correct electrolytes, if QTc is moderately prolonged and to cease the 
15 drug if QTc is markedly prolonged (20).  Also, two recent studies have lighted the risk of QT 
16 interval prolongation in patients with COVID-19 infection treated with hydroxychloroquine. In 
17 a case series of intensive care unit patients (median age= 68 years (IQR, 58-74 years)) 
18 admitted for COVID-19 infection, those treat d with hydroxychloroquine had an increased  risk 
19 of QT prolongation (21). Similar findings were echoed in a cohort study conducted at a tertiary 
20 care hospital in Boston, Massachusetts, involving 90 patients with mean age 60 years 
21 (SD=16). In this cohort study, patients who received hydroxychloroquine for the treatment of 
22 pneumonia associated with COVID-19 were at high risk of QTc prolongation (22).  The most 
23 common underlying comorbidities in this cohort included hypertension and diabetes. 
24 Hydroxychloroquine is known to cause direct myocardial toxicity and cardiomyopathy (23, 24). 
25 Yogasundaram et al. have shown that cardiomyopathy is a preventable complication and early 
26 withdrawal of hydroxychloroquine treatment can potentially result in a partial or complete 
27 reversal of cardiomyopathy (25).
28 Our analyses revealed several other cardiac adverse effects associated with 
29 hydroxychloroquine, including left and right ventricular hypertrophy and acute left ventricular 
30 failure. These are well recognized AEs of hydroxychloroquine. Prescribers should be aware 
31 that these serious adverse events can be pronounced in older adults with pre-existing cardiac 
32 disease. However, our novel findings include the identification of cardiac septal hypertrophy 
33 and myocardial fibrosis associated with hydroxychloroquine therapy, and these signals require 
34 further confirmation. Cardiac septal hypertrophy in older adults is associated with disturbance 
35 in intraventricular conduction and is an independent predictor of progression to atrial fibrillation 
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1 in patients with hypertrophic cardiomyopathy. (26, 27). Myocardial fibrosis is a significant risk 
2 factor for hypertrophic cardiomyopathy, and is associated with a myriad of severe adverse 
3 cardiovascular outcomes including sudden cardiac death, ventricular tachyarrhythmias, left 
4 ventricular dysfunction, and heart failure (28).
5
6 Strengths and limitations 
7 This study used PharmaPendium, a database maintained by Elsevier that curates data from 
8 FAERS. PharmaPendium uses PTs, defined in MedDRA, to identify adverse events from 
9 FAERS. FAERS is a spontaneous reporting system (SRS) widely used for examining 
10 associations between marketed medicines and AEs. SRS is particularly useful when safety 
11 data from randomized controlled trials or observational studies are lacking. Analyses of SRS 
12 can potentially reveal new and clinically important drug-event associations. Rare safety events 
13 can be captured in SRS that is generally not identified in clinical trials. Notably, to our 
14 knowledge, no previous investigations have reported the safety profile of hydroxychloroquine 
15 in older adults.
16
17 There are database and several methodological limitations associated with this study. Adverse 
18 event reports are submitted voluntarily to FAERS, and this may potentially lead to 
19 underreporting (29). Although careful consideration was given to the removal of duplicated 
20 reports, there is a possibility that the AEs may be reported multiple times by various 
21 stakeholders including patients, manufacturers and physicians.   Given the spontaneous 
22 nature of reporting, the drug exposure at a population level is unknown, hence the actual 
23 incidence rate for the AE cannot be established. Lack of information on comorbidities, family 
24 history, and incomplete dosage information is likely to bias the study findings. Characteristic 
25 of SRS is the potential for selective reporting of only serious adverse events. Specific 
26 methodological limitations include examining hydroxychloroquine as the primary drug of 
27 interest without ascertaining the impact of concomitant medications on the AE. Several of the 
28 AEs identified with hydroxychloroquine may be confounded by the severity of the underlying 
29 medical condition. For example, several autoimmune disorders treated with 
30 hydroxychloroquine are independently associated with adverse cardiac outcomes. It is 
31 important to note that we did not investigate a dose-dependent or a temporal relationship with 
32 AEs, as these are significant risk factors for cardiac AEs with hydroxychloroquine. The ROR's 
33 for ADE's associated with hydroxychloroquine with a wide confidence interval represents a 
34 lack of sample size, and the safety signals must be interpreted with this limitation. The safety 
35 signals reported in this study with hydroxychloroquine do not impart causality.
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3 The risk of cardiac disorders is increased with hydroxychloroquine in older adults. Despite, the 
4 lack of causality in our findings, these safety signals must be monitored and where applicable 
5 appropriate screening to mitigate these complications is recommended. The American 
6 College of Cardiology's as well as the Canadian heart rhythm society recommendation is that 
7 patients with COVID-19 infection treated with hydroxychloroquine should undergo a careful 
8 assessment of baseline risk of QT prolongation, including baseline ECG, biochemical tests, 
9 and exclusion of concomitant drugs that have a potential to prolong QTc interval to mitigate 
10 further complications such as torsades de pointes (11). Due to the current lack of randomized 
11 controlled trials as well large observational studies to confirm the risk of AEs associated with 
12 hydroxychloroquine, findings from analyses of post-marketing data may serve as interim 
13 guidance until further robust data on safety becomes available.
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Blood and lymphatic system disorders (n = 110)
Cardiac disorders (n = 334)
Congenital, familial and genetic disorders (n = 11)
Ear and labyrinth disorders (n = 41)
Endocrine disorders (n = 4)
Eye disorders (n = 287)
Gastrointestinal disorders (n = 394)
General disorders and administration site conditions 
(n = 976)
Hepatobiliary disorders (n = 50)
Immune system disorders (n = 78)
Infections and infestations (n = 409)
Injury, poisoning and procedural complications         
(n = 137)
Investigations (n = 376)
Metabolism and nutrition disorders (n = 90)
Musculoskeletal and connective tissue disorders     
(n = 654)
Neoplasms benign, malignant and unspecified (incl 
cysts and polyps) (n = 85)
Nervous system disorders (n = 304)
Psychiatric disorders (n = 132)
Renal and urinary disorders (n = 79)
Reproductive system and breast disorders (n = 4)
Respiratory, thoracic and mediastinal disorders        
(n = 256)
Skin and subcutaneous tissue disorders (n = 415)
Social circumstances (n = 39)
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Atrioventricular block complete (n=8) 
Atrioventricular block first degree(n=6) 
Atrioventricular block second degree (n=1)
Bundle branch block bilateral (n=1)
Bundle branch block left (n=9) 
Bundle branch block right (n=4) 
Conduction disorder (n=1)
Long QT syndrome (n=7) 
Cardiac arrest (n=4)
Cardio-respiratory arrest (n=2)







Sinus node dysfunction (n=2)








Hyperdynamic left ventricle (n=1)
Palpitations (n=13)




Mitral valve disease (n=1)
Mitral valve incompetence (n=3)
Tricuspid valve incompetence (n=3)
Coronary artery disease (n=3)
Coronary artery occlusion (n=3)
Coronary artery stenosis (n=1)
Coronary artery thrombosis (n=1)





Cardiac failure acute (n=4)
Cardiac failure congestive (n=20)
Cardiac failure (n=18)
Left ventricular failure (n=4) 
Acute left ventricular failure (n=4) 
Right ventricular failure (n= 2)
Cardiomyopathy (n=23) 
Congestive cardiomyopathy (n=3)
Restrictive cardiomyopathy (n=10) 
Cardiac hypertrophy(n=4) 
Cardiac septal hypertrophy (n=5) 
Cardiomegaly (n=2)
Diastolic dysfunction (n=7) 
Dilatation atrial (n=5) 
Left atrial dilatation (n=3)
Left ventricular dysfunction (n=5) 
Left ventricular hypertrophy (n=10) 
Myocardial fibrosis (n=4) 
Right atrial dilatation (n=2)
Right ventricular dilatation (n=1)





Pericardial effusion (n=8) 
SOCs HLGTs HLTs PTs
Cardiac 










disorders                 
(n = 17)
Cardiac valve 
disorders                 
(n = 7)
Heart failures              
(n = 52)
Myocardial 
disorders                
(n = 97)
Endocardial 
disorders                
(n = 2)
Pericardial 
disorders                 
(n = 8)
Cardiac conduction disorders 
(n = 41)
Ventricular arrhythmias and 




Rate and rhythm disorders 
NEC  (n = 22)
Cardiac signs and symptoms 
NEC  (n = 15)
Cardiac disorders NEC           
(n =21)
Mitral valvular disorders       
(n = 4)
Tricuspid valvular disorders 
(n = 3)
Coronary artery disorders 
NEC (n = 8)
Ischaemic coronary artery 
disorders (n = 9)
Endocardial disorders NEC   
(n = 2)
Myocardial disorders NEC     
(n = 60)
Cardiomyopathies                  
(n = 36)
Heart failures NEC (n = 42)
Left ventricular failures         
(n = 8)
Right ventricular failures        
(n = 2)
Non-infectious myocarditis    
(n = 1)
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Bundle branch block right
Bundle branch block left
Atrioventricular block first degree
Atrioventricular block complete
Acute left ventricular failure
4 32 256



























































































































Bundle branch block right
Bundle branch block left
Atrioventricular block first degree
Atrioventricular block complete
Acute left ventricular failure
4 32 256
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2 Purpose The purpose of this study is to analyse analyze the US FDA Adverse Event 
3 Reporting System (FAERS) to identify adverse cardiac events of hydroxychloroquine in older 
4 adults.
5 Method A case/non-case method was used to determine adverse events associated with 
6 hydroxychloroquine as the primary suspect drug between January 1, 2004,2004-01-01 and 
7 December 31, 2019,2019-12-01 for older adults (≥ 65 years). Adverse events are preferred 
8 terms (PTs) defined in MedDRA. We used frequentist approaches, including the reporting 
9 odds ratio (ROR) and the proportional reporting ratio (PRR) to measure disproportionality. We 
10 used Bayesian approaches to derive information component (IC) value and Empirical 
11 Bayesian Geometric Mean (EBGM) score. Signals were defined as the number of reports>3 
12 and the lower limit of 95% confidence intervals (CI) of ROR ≥2, PRR ≥2, IC >0, EBGM>1 
13 Results We identified 334 adverse cardiac events comprising 71 different MedDRA PTs from 
14 2004 to 2019 for hydroxychloroquine in older adults. Strong disproportionality signals were 
15 noted for ‘Restrictive cardiomyopathy’ (ROR= 272.43 (138.09-537.47); EBGM= 149.78 
16 (77.34-264.67), ‘Right ventricular hypertrophy’ (219.49 (85.32-564.70); 102.74 (39.67-
17 222.81), ‘Cardiac septal hypertrophy’ (226.77 (78.65-653.80); 93.82 (32.19-219.81), 
18 ‘Myocardial fibrosis’ (57.29 (21.06-155.85); 42.99 (14.74-100.75), and ‘Cardiotoxicity’ (43.90 
19 (26.66-72.27); 40.28 (24.02-63.72).
20 Conclusions The risk of cardiomyopathy and myocardial disorders is high following exposure 
21 to hydroxychloroquine in older adults. Due to the current lack of safety data from randomised 
22 randomized controlled trials as well as large observational studies to confirm the risk of 
23 adverse cardiac events associated with hydroxychloroquine, findings from analyses of post-
24 marketing data  may serve as interim guidance.
25
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2 The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 
3 (SARS-CoV-2) has positioned drug repurposing research on the spotlight (1, 2). Drug 
4 repurposing is investigating existing drugs for new indications, and several drugs have 
5 emerged as candidates for repurposing to treat COVID-19. Among the several The leading 
6 candidates are azithromycin, chloroquine, hydroxychloroquine , ivermectin, lopinavir/ritonavir 
7 and remedesivir have . Amongst these, hydroxychloroquine has generated massive interest 
8 in the USA as a potential ‘'game-changer’ changer' in the treatment of COVID-19 (3, 4). 
9 Several clinical trials are being undertaken to generate evidence on the efficacy of 
10 hydroxychloroquine to treat COVID-19 patients (5).  Based on the research evidence from 
11 ongoing clinical trials, the US FDA  has removed the emergency use authorization for 
12 hydroxychloroquine and chloroquine for the treatment of COVID-19 given that the risks of 
13 using hydroxychloroquine for the treatment of COVID-19 infection outweigh any benefits (6). 
14 However, the uncertainty of the safety of hydroxychloroquine in older adults will endure given 
15 the historical evidence for the exclusion of older adults with comorbidities in clinical trials. 
16 COVID-19 disproportionately affects older adults. Given the repurposing of 
17 hydroxychloroquine has gainedis gaining rapid interest for the treatment of COVID-19, 
18 understanding safety profile of hydroxychloroquine from post-marketing data is of paramount 
19 importance. This is particularly important as there is a lack of safety data for 
20 hydroxychloroquine from randomised randomized controlled trials (RCTs) or observational 
21 studies (7). Specifically, there is a lack of safety data from RCTs for older adults using 
22 hydroxychloroquine for the treatment of COVID-19 infection caused by SARS-CoV-2 (8, 9). A 
23 recent RCT conducted in USA and Canada showed that hydroxychloroquine was not effective 
24 when offered as prophylaxis after COVID-19 exposure. In this RCT (N=821), the median age 
25 of the study population was 41 (IQR=33 to 51) years with no safety data reported for 
26 hydroxychloroquine use in older adults (9).  A more recent RCT conducted over eight weeks 
27 that evaluated the efficacy and safety of hydroxychloroquine versus placebo for pre-exposure 
28 SARS-CoV-2 prophylaxis among health care workers showed no clinical benefit of 
29 hydroxychloroquin (10). The median age of the study population in this RCT was 33 (20-66), 
30 and there was no safety data for hydroxychloroquine reported in older adults.  The objective 
31 of this study is to analyse analyze the US FDA Adverse Event Reporting System (FAERS), a 
32 publicly available database, to identify adverse cardiovascular events of hydroxychloroquine 
33 in older adults using analysis of disproportionality. The FAERS data is widely used in drug 
34 safety research for exploratory analyses to generate hypotheses and safety signals reported 
35 do not impart causality. 
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2 Ethics approval: The Departmental Research Ethical Officer at the University of Bath 
3 approved this study. 
4 Data source: Data was retrieved from the Elsevier PharmaPendium database (11). Data for 
5 4667+ United States FDA and European Medicines Agency approved drugs, and 14+ million 
6 FAERS reports have been collected and stored in the PharmaPendium in the latest 2020.07 
7 release. The use of PharmaPendium for drug safety research is described elsewhere (12, 13). 
8 Each FAERS report contains information on the drug and its role in the event, dose, frequency 
9 and route. The primary, secondary, concomitant and interacting drugs are reported. .
10 Along with the adverse event experienced, the outcome, drug indication, reporter occupation, 
11 location of the event, manufacturer, patient gender and age are documented.  Each report has 
12 an AERS report number and Case ID aiding with easy identification. The Medical Dictionary 
13 for Regulatory Activities (MedDRA) was used to identify frequently implicated adverse drug 
14 events. 
15 Adverse drug reaction definition
16 We used the preferred terms (PTs) recommended in the Medical Dictionary of Regulatory 
17 Activities (MedDRA v2.0) to define adverse events associated with hydroxychloroquine. Each 
18 PT is part of the hierarchal system, linking to a higher-level term (HLT), higher-level group 
19 term (HLGT) and system organ class (SOC). 
20
21 Statistical Analyses
22 We selected hydroxychloroquine as the primary suspect drug and analysed analyzed all 
23 reported adverse events in older adults from the start of January 1, 2004,2004-01-01 to the 
24 end of December 31, 20192019-12-31. The ratio of cases/non-cases for hydroxychloroquine 
25 were was compared with the ratio of cases/non-cases for all other drugs for the same study 
26 period. We used the disproportionality analyses to calculate the reporting odds ratio (ROR) 
27 and the proportional reporting ratio (PRR) (14). We used the Bayesian approach to calculate 
28 information component (IC) values and Empirical Bayesian Geometric Mean (EBGM) scores. 
29 The criteria for a disproportionality signal was defined as the number of reports >3 and the 
30 lower limit of 95% confidence intervals (CI) of ROR ≥2, PRR value ≥2, IC value >0 and EBGM 
31 score >1. For secondary analyses, we mapped the PTs of adverse cardiovascular events to 
32 system organ class (SOC), high-level group term (HLGT) and high-level term (HLT). Analysis 
33 The analysis was conducted in R, version 3.6.1 (15).
34
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2 We retrieved a total of 7,247,902 drug-event pairs between January 1, 2004, 2004-01-01 and 
3 December 31, 2019, 2019-12-31 recorded in FAERS for adults aged ≥ 65 years by splitting 
4 multiple AEs reported for each case. Of which, 5327 adverse events (AEs) belonged to 
5 hydroxychloroquine. Amongst the 5327 AEs, we identified 334 adverse cardiac events 
6 comprising 71 different MedDRA PTs. The mean age of the patients within the reports 
7 (n=1090) for hydroxychloroquine is 71.77 (7.27) years, and 85.4 % were females. 56.1% of 
8 the reports were submitted by ‘'other healthcare professionals’ professionals' followed by 
9 20.3% from physicians and 20.5% from consumers. 90.4% of the reports were expedited. The 
10 country of origin of the reports was mostly from the USA.  Indications were missing for 97 out 
11 of 1090 (8.9%) reports. The majority of the reports 430/1090 (39.4%) indicated 
12 hydroxychloroquine was used for rheumatic disorders (mainly rheumatoid arthritis) followed 
13 by 124/1090 (11.3%) reports for systemic lupus erythematosus, and 199/1090 (18.3%) reports 
14 recorded hydroxychloroquine was used for an unknown indication.
15 Figure 1. Mapping of hydroxychloroquine-associated all adverse drug events at different 
16 MedDRA levels: SOC: system organ class; HLGT: high-level group term; HLT: high-level term
17 Figure 2. Mapping of hydroxychloroquine-associated cardiovascular events at different 
18 MedDRA levels: SOC: system organ class; HLGT: high-level group term; HLT: high-level term. 
19 Yellow boxes include terms resulting in disproportionality signals, ; Grey boxes include terms 
20 without disproportionality; NEC: not elsewhere classified; MedDRA: Medical Dictionary for 
21 Regulatory Activities
22
23 Figure 3: RORs and EBGM scores with 95% CIs for PTs with hydroxychloroquine-
24 associated cardiovascular events. ADR-adverse drug reaction; HCQ-hydroxychloroquine 
25 ROR- reporting odds ratio; EBGM-Empirical Bayesian geometric mean; CI confidence 
26 interval.
27 Strong disproportionality signals were noted for ‘Restrictive cardiomyopathy’ (ROR= 272.43 
28 (138.09-537.47); EBGM= 149.78 (77.34-264.67), ‘Right ventricular hypertrophy’ (219.49 
29 (85.32-564.70); 102.74 (39.67-222.81), ‘Cardiac septal hypertrophy’ (226.77 (78.65-653.80); 
30 93.82 (32.19-219.81), ‘Myocardial fibrosis’ (57.29 (21.06-155.85); 42.99 (14.74-100.75), and 
31 ‘Cardiotoxicity’ (43.90 (26.66-72.27); 40.28 (24.02-63.72).
32 Discussion
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1 The risk for severe illnesses from COVID-19 infection is age-related, with older adults aged 
2 85 or older at highest risk. Underlying medical comorbidities, specifically underlying 
3 cerebrovascular and cardiovascular disease, including heart failure, coronary heart disease 
4 and cardiomyopathies, increases the risk of hospitalizations and intensive care unit 
5 admissions in older adults with COVID-19 infection (16). In this context, tThis study addressed 
6 the impending necessity emerging from the COVID-19 pandemic for understanding the safety 
7 of  hydroxychloroquine in older adults. 
8
9 Majority of the cardiovascular AEs reported in this study are related to cardiac conduction and 
10 myocardial disorders. These findings are consistent with a recent systematic review that 
11 concluded conduction disorders and myocardial hypertrophy as two major cardiac 
12 complications associated with hydroxychloroquine therapy (17). 
13 Analyses of high-level MedDRA terms suggest that hydroxychloroquine therapy is associated 
14 with abnormal cardiac conduction, cardiac arrhythmias, and cardiomyopathy.  Several case 
15 reports have described proarrhythmic effects and signs of long QT syndrome following 
16 hydroxychloroquine exposure in patients with systemic lupus erythematosus (18, 19). The 
17 interim guidance from the Canadian heart rhythm society to mitigate drug-induced arrhythmias 
18 is for performing baseline ECG testing in high-risk patients. The recommendation is to optimise 
19 optimize drug treatments, and correct electrolytes, if QTc is moderately prolonged and to 
20 cease the drug if QTc is markedly prolonged (20).  Also, two recent studies have lighted the 
21 risk of QT interval prolongation in patients with COVID-19 infection treated with 
22 hydroxychloroquine. In a case series of intensive care unit patients (median age= 68 years 
23 (IQR, 58-74 years)) admitted for COVID-19 infection, those treated with hydroxychloroquine 
24 had an increased  risk of QT prolongation (21). Similar findings were echoed in a cohort study 
25 conducted at a tertiary care hospital in Boston, Massachusetts, involving 90 patients with 
26 mean age 60 years (SD=16). In this cohort study, patients who received hydroxychloroquine 
27 for the treatment of pneumonia associated with COVID-19 were at high risk of QTc 
28 prolongation (22).  The most common underlying comorbidities in this cohort included 
29 hypertension and diabetes. 
30 Hydroxychloroquine is known to cause direct myocardial toxicity and cardiomyopathy (23, 24). 
31 Yogasundaram et al. have shown that cardiomyopathy is a preventable complication and early 
32 withdrawal of hydroxychloroquine treatment can potentially result in a partial or complete 
33 reversal of cardiomyopathy (25).
34 Our analyses revealed several other cardiac adverse effects associated with 
35 hydroxychloroquine, including left and right ventricular hypertrophy and acute left ventricular 
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1 failure. These are well recognised recognized AEs of hydroxychloroquine. Prescribers  should 
2 be aware that these serious adverse events can be pronounced in older adults with pre-
3 existing cardiac disease. However, our novel findings include the identification of cardiac 
4 septal hypertrophy and myocardial fibrosis associated with hydroxychloroquine therapy, and 
5 these signals require further confirmation. Cardiac septal hypertrophy in older adults is 
6 associated with disturbance in intraventricular conduction and is an independent predictor of 
7 progression to atrial fibrillation in patients with hypertrophic cardiomyopathy. (26, 27). 
8 Myocardial fibrosis is a significant risk factor for hypertrophic cardiomyopathy, and is 
9 associated with a myriad of severe adverse cardiovascular outcomes including sudden 
10 cardiac death, ventricular tachyarrhythmias, left ventricular dysfunction, and heart failure (28).
11
12 Strengths and limitations 
13 This study used PharmaPendium, a database maintained by Elsevier that curates data from 
14 FAERS. PharmaPendium uses PTs, defined in MedDRA, to identify adverse events from 
15 FAERS. FAERS is a spontaneous reporting system (SRS) widely used for examining 
16 associations between marketed medicines and AEs. SRS is particularly useful when safety 
17 data from randomised randomized controlled trials or observational studies are lacking. 
18 Analyses of SRS can potentially reveal new and clinically important drug-event associations. 
19 Rare safety events can be captured in SRS that are is generally not identified in clinical trials. 
20 ImportantlyNotably, to our knowledge, no previous investigations have reported the safety 
21 profile of hydroxychloroquine in older adults.
22
23 There are several database and several methodological limitations associated with this study. 
24 Adverse event reports are submitted on a voluntary basisvoluntarily to FAERS, and this may 
25 potentially lead to underreporting (29). Although careful consideration was given to the 
26 removal of duplicated reports, there is a possibility that the AEs may be reported multiple times 
27 by various stakeholders including patients, manufacturers and physicians.   Given the 
28 spontaneous nature of reporting, the drug exposure at a population level is unknown, hence 
29 the actual incidence rate for the AE cannot be established. Lack of information on 
30 comorbidities, family history, and incomplete dosage information is likely to bias the study 
31 findings. Characteristic to of SRS is the potential for selective reporting of only serious adverse 
32 events. Specific methodological limitations include examining hydroxychloroquine as the 
33 primary drug of interest without ascertaining the impact of concomitant medications on the AE. 
34 Several of the AEs identified with hydroxychloroquine may be confounded by the severity of 
35 the underlying medical condition. For example, several autoimmune disorders treated with 
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1 hydroxychloroquine are independently associated with adverse cardiac outcomes. It is 
2 important to note that we did not investigate a dose-dependent or a temporal relationship with 
3 AEs, as these are significant risk factors for cardiac AEs with hydroxychloroquine. The ROR's 
4 for ADE's associated with hydroxychloroquine with a wide confidence interval represents a 
5 lack of sample size, and the safety signals must be interpreted with this limitation. The safety 
6 signals reported in this study with hydroxychloroquine do not impart causality.
7
8 Conclusions
9 The risk of cardiac disorders is increased with hydroxychloroquine in older adults. Despite, the 
10 lack of causality in our findings, these safety signals must be monitored and where applicable 
11 appropriate screening to mitigate these complications is recommended. The American 
12 College of Cardiology's as well as the Canadian heart rhythm society recommendation is that 
13 patients with COVID-19 infection treated with hydroxychloroquine should undergo a careful 
14 assessment of baseline risk of QT prolongation, including baseline ECG, biochemical tests, 
15 and exclusion of concomitant drugs that have a potential to prolong QTc interval to mitigate 
16 further complications such as torsades de pointes (11). Due to the current lack of randomised 
17 randomized controlled trials as well large observational studies to confirm the risk of AEs 
18 associated with hydroxychloroquine, findings from analyses of post-marketing data may serve 
19 as an interim guidance until further robust data on safety becomes available.
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